Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson (JNJ)
Price$270.68Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | $71.31B | $67.22B | $65.03B | $61.59B | $61.90B | $63.75B | $61.09B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.80B | $43.45B | $45.24B | $43.34B |
| Gross margin | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% |
| Research & development | $14.66B | $17.23B | $15.09B | $14.13B | $14.28B | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B |
| Operating expenses | $38.34B | $40.10B | $36.60B | $34.38B | — | — | — | — | — | — | — | $30.00B | $32.56B | $30.61B | $30.91B | $25.09B | $26.87B | — | — |
| Operating income | $25.60B | $21.25B | $22.01B | $21.01B | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.70B | $16.58B | — | — |
| Operating margin | 27.17% | 23.92% | 25.84% | 26.27% | — | — | — | — | — | — | — | 29.05% | 23.01% | 22.25% | 21.17% | 28.74% | 26.79% | — | — |
| EBITDA | $41.05B | $24.78B | $23.32B | $26.61B | — | — | — | — | — | — | — | $25.48B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | — | — |
| EBITDA margin | 43.59% | 27.90% | 27.38% | 33.26% | — | — | — | — | — | — | — | 34.29% | 28.77% | 27.70% | 26.02% | 33.51% | 31.27% | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B |
| Net profit margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% |
| Basic EPSper basic share | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| Diluted EPSper diluted share | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BlackRock, Inc. | 212.1M |
VANGUARD CAPITAL MANAGEMENT LLC | 157.23M |
STATE STREET CORP | 133.78M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 64.37M |
GEODE CAPITAL MANAGEMENT, LLC | 59.09M |
JPMORGAN CHASE & CO | 58.3M |
MORGAN STANLEY | 44.81M |
NORGES BANK | 31.83M |
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31.59M |
NORTHERN TRUST CORP | 28.79M |
BANK OF AMERICA CORP /DE/ | 23.44M |
PRICE T ROWE ASSOCIATES INC /MD/ | 23M |
FMR LLC | 22.6M |
WELLINGTON MANAGEMENT GROUP LLP | 22.59M |
Bank of New York Mellon Corp | 21.68M |
GOLDMAN SACHS GROUP INC | 19.72M |
Legal & General Group Plc | 19.29M |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19.13M |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18.42M |
WELLS FARGO & COMPANY/MN | 17.37M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 | Wengel Kathryn EEVP, Chief TO and Risk Officer | SellCommon Stock | 10.0K | $241.15 | $2.41M | 114.3K |
| Feb 27, 2026Form 4 | Decker Robert JVP Corporate Controller | SellCommon Stock | 4.1K | $247.87 | $1.01M | 23.7K |
| Feb 20, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 1.3K | $245.66 | $324.8K | 25.4K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 9.0K | $244.53 | $2.20M | 26.8K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 13.6K | $244.20 | $3.33M | 26.8K |
Community posts
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
